Vivek Subbiah: Presenting the story of Hydra and Cancer
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute in the USA, posted on X:
“Presenting the story of Hydra and Cancer – ‘Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer. Acquired NTRK3 fusion, ALK fusion, NTRK3 solvent-front mutation as secondary, tertiary, and quaternary off-target resistance mechanisms’ Cancer – akin to the mythical Hydra, whose 9 heads must be all severed, as two heads grow back if one is slayed.
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET-driven cancer | Precision Oncology
Battling the 9-headed cancer Hydra (akin to Cancer) with multiple modalities. Cutting off a head may result in two heads growing back (akin to the emergence of resistance mutations when a single mutation is targeted).”
Read further.
Source: Vivek Subbiah/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023